Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1050260

	registered interest
	date	28/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Yorkshire Ambulance Service NHS Trust
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what proportion of calls were responded to within the target timeframe in the area covered by Yorkshire Ambulance Service NHS Trust in each of the categories measured (a) in total and (b) in each by District Council Area Level in each month of 2018.
	tabling member constituency	Keighley
	tabling member printed	John Grogan
	uin	213223
	answer	answer is ministerial correction date of answer 04/02/2019 answer text <p>NHS England’s Ambulance Quality Indicators set out Yorkshire Ambulance Service NHS Trust performance against each of the categories measured in each month of 2018. The data is attached.</p><p> </p><p>Data by District Council area is not collected centrally. Ambulance response times are published monthly by NHS England at ambulance trust level.</p><p> </p><p>Data can be found online at the following address:</p><p> </p><p><a href="https://www.england.nhs.uk/statistics/statistical-work-areas/ambulance-quality-indicators/" target="_blank">https://www.england.nhs.uk/statistics/statistical-work-areas/ambulance-quality-indicators/</a></p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 04/02/2019 14:54:59 answering member 1585 label Biography information for Stephen Hammond attachment 1 file name PQ213223 - data table.xlsx.docx title PQ213223 attached data
	tabling member	382 label Biography information for John Grogan

1054826

	registered interest
	date	04/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Yellow Fever: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make representations to Sanofi Pasteur on undertaking new research into the risks of adverse events, including psychosis, from using the vaccine Stamaril.
	tabling member constituency	Gravesham
	tabling member printed	Adam Holloway
	uin	216210
	answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>As with all vaccines and medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) closely monitors the safety of Stamaril yellow fever vaccine. The MHRA takes advice from the Government's independent scientific advisory body, the Commission on Human Medicines, when evaluating the risks and benefits of medicines and vaccines.</p><p> </p><p>The Marketing Authorisation Holder for Stamaril, Sanofi Pasteur, has statutory obligations to continuously monitor the safety, and balance of benefits and risks, of the vaccine.</p><p> </p><p>The potential risks of Stamaril are described in the prescribing information, the Summary of Product Characteristics, and the information for vaccine recipients, the Patient Information Leaflet. A recognised, very rare risk of Stamaril vaccine is Yellow Fever Vaccine-Associated Neurotropic Disease, known as YEL-AND. Whilst the symptoms of YEL-AND can include confusion and acute focal neurological deficits (e.g. affecting motor co-ordination), this is not typically associated with psychosis or other long-term psychiatric disorders.</p><p> </p><p>Further to other recent reports of serious suspected adverse reactions in United Kingdom travellers, the MHRA is in the process of further reviewing the balance of benefits and risks of Yellow Fever vaccine, which will include an analysis of neuropsychiatric events.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 216211 216213 question first answered 12/02/2019 17:04:11 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1522 label Biography information for Adam Holloway

1054828

	registered interest
	date	04/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Yellow Fever: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what representations he has made to Sanofi Pasteur on ensuring that new technology is developed to eliminate the risks of adverse events, including psychosis, from the use of the vaccine Stamaril.
	tabling member constituency	Gravesham
	tabling member printed	Adam Holloway
	uin	216211
	answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>As with all vaccines and medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) closely monitors the safety of Stamaril yellow fever vaccine. The MHRA takes advice from the Government's independent scientific advisory body, the Commission on Human Medicines, when evaluating the risks and benefits of medicines and vaccines.</p><p> </p><p>The Marketing Authorisation Holder for Stamaril, Sanofi Pasteur, has statutory obligations to continuously monitor the safety, and balance of benefits and risks, of the vaccine.</p><p> </p><p>The potential risks of Stamaril are described in the prescribing information, the Summary of Product Characteristics, and the information for vaccine recipients, the Patient Information Leaflet. A recognised, very rare risk of Stamaril vaccine is Yellow Fever Vaccine-Associated Neurotropic Disease, known as YEL-AND. Whilst the symptoms of YEL-AND can include confusion and acute focal neurological deficits (e.g. affecting motor co-ordination), this is not typically associated with psychosis or other long-term psychiatric disorders.</p><p> </p><p>Further to other recent reports of serious suspected adverse reactions in United Kingdom travellers, the MHRA is in the process of further reviewing the balance of benefits and risks of Yellow Fever vaccine, which will include an analysis of neuropsychiatric events.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 216210 216213 question first answered 12/02/2019 17:04:11 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1522 label Biography information for Adam Holloway

1054829

	registered interest
	date	04/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Yellow Fever: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will commission research into new vaccines for yellow fever in the event that Sanofi Pasteur does not undertake research into its yellow fever vaccine.
	tabling member constituency	Gravesham
	tabling member printed	Adam Holloway
	uin	216212
	answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The Department’s National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including the development of cheaper vaccines. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality. In all disease areas, the amount of NIHR funding depends on the volume and quality of scientific activity.</p><p> </p><p>The NIHR and the Medical Research Council both have a wide portfolio of research activity in vaccines which cover clinical trials for new vaccines, new technologies, ways of improving uptake and cost effectiveness.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 12/02/2019 16:24:27 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	1522 label Biography information for Adam Holloway

1054830

	registered interest
	date	04/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Yellow Fever: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of including psychosis in the list of potential side effects published on the use of Stamaril as a vaccine for yellow fever.
	tabling member constituency	Gravesham
	tabling member printed	Adam Holloway
	uin	216213
	answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>As with all vaccines and medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) closely monitors the safety of Stamaril yellow fever vaccine. The MHRA takes advice from the Government's independent scientific advisory body, the Commission on Human Medicines, when evaluating the risks and benefits of medicines and vaccines.</p><p> </p><p>The Marketing Authorisation Holder for Stamaril, Sanofi Pasteur, has statutory obligations to continuously monitor the safety, and balance of benefits and risks, of the vaccine.</p><p> </p><p>The potential risks of Stamaril are described in the prescribing information, the Summary of Product Characteristics, and the information for vaccine recipients, the Patient Information Leaflet. A recognised, very rare risk of Stamaril vaccine is Yellow Fever Vaccine-Associated Neurotropic Disease, known as YEL-AND. Whilst the symptoms of YEL-AND can include confusion and acute focal neurological deficits (e.g. affecting motor co-ordination), this is not typically associated with psychosis or other long-term psychiatric disorders.</p><p> </p><p>Further to other recent reports of serious suspected adverse reactions in United Kingdom travellers, the MHRA is in the process of further reviewing the balance of benefits and risks of Yellow Fever vaccine, which will include an analysis of neuropsychiatric events.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 216210 216211 question first answered 12/02/2019 17:04:11 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1522 label Biography information for Adam Holloway

1054831

	registered interest
	date	04/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Yellow Fever: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits on including yellow fever in the list of vaccines under the Vaccine Damage Payment Act 1979 for which compensation may be paid.
	tabling member constituency	Gravesham
	tabling member printed	Adam Holloway
	uin	216214
	answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The Vaccine Damage Payment Scheme (VDPS) is not a compensation scheme. There is no assessment of what losses were actually suffered. It provides a one off tax-free lump sum payment, currently £120,000, to successful claimants and is one part of the wide range of support and help available to severely disabled people in the United Kingdom.</p><p> </p><p>The VDPS is primarily designed to cover adverse reactions for vaccination in the child immunisation programme which is a Government initiative to protect the community from infectious disease and does not include travel vaccines.</p><p> </p><p>The Scheme is being kept under review if further inclusions are thought necessary.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/02/2019 11:47:07 answering member 4067 label Biography information for Steve Brine
	tabling member	1522 label Biography information for Adam Holloway

1054839

	registered interest
	date	04/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Yellow Fever: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what information he holds on research into safer alternatives to the Stamaril vaccine; and if the Government will provide funding for such research.
	tabling member constituency	Gravesham
	tabling member printed	Adam Holloway
	uin	216216
	answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The Medical Research Council has an active study to assess the safety and immunogenicity of yellow fever vaccine dose sparing strategies for campaign and programmatic use. The study seeks to determine whether using a fractional dose of the normal yellow fever vaccine in infants provides sufficient protection against yellow fever compared with the normal dose of vaccine and whether altering the route of administration affects vaccine safety.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 12/02/2019 16:59:08 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1522 label Biography information for Adam Holloway

1122670

	registered interest
	date	24/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	X-rays
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of whether hospitals frequently need to rely on the family members of patients to assist in x-ray procedures.
	tabling member constituency	North East Hampshire
	tabling member printed	Mr Ranil Jayawardena
	uin	247137
	answer	answer is ministerial correction date of answer 02/05/2019 answer text <p>The Department has made no such assessment.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 02/05/2019 13:40:28 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4498 label Biography information for Mr Ranil Jayawardena

1059628

	registered interest
	date	12/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Wound Dressings
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether additional financial support is planned to support the National Wound Care Strategy Programme beyond September 2019.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL13650
	answer	answer is ministerial correction date of answer 26/02/2019 answer text <p>The National Wound Care Strategy Programme (NWCSP) aims to improve the quality of wound care provision through developing pathways of care for priority clinical issues and improving the supply and distribution of wound care products.</p><p>The Government and National Health Service fully recognise the benefits of improving the quality of wound care provision, and the role the implementation of the NWCSP will play in achieving this aim. Decisions about the future funding for the NWCSP will be made as part of the implementation of the NHS Long Term Plan.</p> answering member printed Baroness Blackwood of North Oxford question first answered 26/02/2019 13:39:01 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1059629

	registered interest
	date	12/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Wound Dressings
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what progress has been made by the National Wound Care Strategy Programme.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL13651
	answer	answer is ministerial correction date of answer 26/02/2019 answer text <p>The National Wound Care Strategy Programme (NWCSP) has three clinical workstreams (Pressure Ulcers, Lower Limb, Surgical Wounds) and four enabler workstreams (Education and Workforce, Research, Data and Information, Supply and Distribution). Over 80 leading clinicians, researchers, supply and procurement specialists and policy makers are involved in the workstreams, and have commenced work to deliver the programme.</p><p>The NWCSP has a public web page, which includes further information on the strategy. The web page is being further developed and will include regular updates on the progress of the Programme. The NWCSP web page is available as part of the Academic Health Science Networks (AHSN) publicly available website.</p> answering member printed Baroness Blackwood of North Oxford question first answered 26/02/2019 13:37:21 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath